ASH: Targeted oral therapy reduced disease burden and improved symptoms for patients with rare blood disorder
University of Texas MD Anderson Cancer CenterThe targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis.